Novartis last year paid a firm controlled by Michael Cohen, President Trump’s personal lawyer, $100,000 a month for what the Swiss drug maker said was advice on “health care policy matters.”
The company said it ended its relationship with the firm, called Essential Consultants, following a single meeting with Cohen in March of 2017. But it continued paying the firm to comply with terms of the contract until it expired in February of this year, according to Novartis. That would mean Essential Consultants ultimately received payments of $1.2 million.
“Following this initial meeting, Novartis determined that Michael Cohen and Essential Consultants would be unable to provide the services that Novartis had anticipated related to U.S. health care policy matters and the decision was taken not to engage further,” the company said in a statement.
Novartis also said federal investigators working with special counsel Robert Mueller contacted the company in November regarding its connection to Essential Consultants and that it cooperated with the probe.
A source familiar with the situation said Cohen approached then-Novartis CEO Joseph Jimenez shortly after Mr. Trump was elected president. Specifically, Cohen said he could offer advice on how to gain access to members of the incoming administration. Novartis agreed to retain the lawyer’s firm in hopes of gleaning insights into the new regime, the source said.
Novartis’ relationship with Cohen emerged Tuesday after Michael Avenatti, the lawyer for adult film actress Stormy Daniels, claimed tomade to a bank account in Cohen’s name.
Other companies that made financial payments to Essential Consulting include AT&T, Korea Aerospace Industries and an investment firm linked to Russian oligarch Viktor Vekselberg.
In a seven-page memo released on Twitter on Tuesday, Avenatti said AT&T paid Essential Consulting a total of $200,000 in a series of $50,000 payments, dating from 2017 to early this year.
CBS News has reviewed financial documents that appear to support Avenatti’s account of the transactions.
Separately, in a statement Wednesday evening provided to CBS News, AT&T confirmed it had been in contact with Mueller.
“When we were contacted by the Special Counsel’s office regarding Michael Cohen, we cooperated fully, providing all information requested in November and December of 2017. A few weeks later, our consulting contract with Cohen expired at the end of the year. Since then, we have received no additional questions from the Special Counsel’s office and consider the matter closed.”
In an email sent to employees on Wednesday, AT&T said it hired “several consultants to help us understand how the president and his administration might approach a wide range of policy issues important to the company. …” Those issues included regulatory matters at the Federal Communications Commission, corporate tax reform and antitrust enforcement, the company said, adding that companies commonly hire consultants for such purposes around the time a new president takes office.
The email was first reported by the Dallas News.
CBS News has not been able to verify all of the claims made by Avenatti. Michael Cohen did not respond to CBS News’ requests for comment.
President Trump’s attorney, Rudy Giuliani, told CBS News that the documents provided by Avenatti include “no allegations against the president” and “no clear allegations of a crime.” Giuliani also said it was his “impression” that Mr. Trump was not aware that Cohen had approached companies offering access to administration officials.
Essential Consultants, which Avenatti said was established in October 2016 just before the presidential election, later made a $130,000 payment to Daniels not to disclose a 2006 sexual encounter with Mr. Trump.
In its statement, Novartis said it engaged Essential Consultants before the company’s CEO, Vas Narasimhan, took the helm earlier this year. It also denied the agreement with Cohen was linked to a dinner Narasimhan had in January with Mr. Trump and other corporate executives at the World Economic Forum in Davos, Switzerland.
“Suggestions to the contrary clearly misrepresent the facts and can only be intended to further personal or political agendas as to which Novartis should not be a part,” the company said, adding that it considers the matter “closed.”
— Paula Reid in Washington contributed to this report